ANTI-PROLIFERATIVE EFFECTIVENESS OF LERCANIDIPINE AND ITS MECHANISM OF ACTION (EXPERIMENTAL STUDY)

Lercanidipine, a calcium channel antagonist, is currently employed in the treatment of essential hypertension and angina pectoris. The purpose of this study was to elucidate the anti-proliferative effect of lercanidipine and to investigate the molecular role of this agent. Both in vitro studies and in a balloon injury rat carotid artery model were employed to study the effect of lercanidipine on smooth muscle cell proliferation. Lercanidipine-inhibited rat vascular smooth muscle cell (VSMC) proliferation and migration in a dose-dependent manner following stimulation of VSMC cultures with 10% fetal bovine serum (FBS) and 20 ng/ml platelet-derived growth factor (PDGF)-BB. FBS- and PDGF-BB-stimulated intracellular Ras, MEK1/2, ERK1/2, proliferative cell nuclear antigen (PCNA), and Akt activations were significantly inhibited by lercanidipine; however, lercanidipine did not affect FBS- and PDGF-BB-induced STAT3 phosphorylation. Lercanidipine also inhibited PDGF-receptor b chain phosphorylation and reactive oxygen species (ROS) production induced by PDGF-BB. Lercanidipine blocked the FBS-inducible progression through the G0/G1 to the S-phase of the cell cycle in synchronized cells. In vivo, 14 days after balloon injury, treatment with 3 and 10 mg/kg lercanidipine resulted in significant inhibition of the neointima/media ratio. Suppression of neointima formation by lercanidipine was dependent on its influence on ERK1/2 phosphorylation. These results demonstrate that lercanidipine can suppress the proliferation of VSMCs via inhibiting cellular ROS, Ras-MEK1/2- ERK1/2, and PI3K-Akt pathways, and suggesting that it may have therapeutic relevance in the prevention of human restenosis.

Lercanidipine, vascular smooth muscle cells, platelet-derived growth factor, MAP kinase, reactive oxygen species

1. Ross R. Atherosclerosis–an inflammatory disease. N Engl J Med 1999; 340:115–26.

2. Corsini A, Bonfatti M, Quarato P, Accomazzo MR, Raiteri M, Sartani A, et al. Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes. J Cardiovasc Pharmacol 1996;28:687–94.

3. Corsini A, Accomazzo MR, Canavesi M, Sartani A, Testa R, Catapano AL, et al. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis in vitro: is calcium entry involved? Blood Press Suppl 1998;2:18–22.

4. HirataA, Igarashi M, Yamaguchi H, SuwabeA, Daimon M, Kato T, et al. Nifedipine suppresses neointimal thickening by its inhibitory effect on vascular smooth muscle cell growth via a MEK-ERK pathway coupling with Pyk2. Br J Pharmacol 2000;131:1521–30.

5. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-termtrial. Circulation 2002;106:2422–7.

6. Raines EW. PDGF and cardiovascular disease. Cytokine & Growth Factor Rev 2004;15:237–54.

7. Millette E, Rauch BH, Kenagy RD, Daum G, Clowes AW. Plateletderived growth factor-BB transactivates the fibroblast growth factor receptor to induce proliferation in human smooth muscle cells. Trends Cardiovasc Med 2006;16: 25–8.

8. Chen XL, Chen ZS, Ding Z, Dong C, Guo H, Gong NQ. Antisense extracellular signal-regulated kinase-2 gene therapy inhibits plateletderived growth factor-induced proliferation, migration and transforming growth factor-beta (1) expression in vascular smooth muscle cells and attenuates transplant vasculopathy. Transpl Int 2008;21:30–8.

9. Guarneri L, Sironi G, Angelico P, Ibba M, Greto L, Colombo D, et al. In vitro and in vivo vascular selectivity of lercanidipine and its enantiomers. J Cardiovasc Pharmacol 1997;29: S25–32.

10. Cominacini L, Fratta Pasini A, Garbin U, Pastorino AM, Davoli A, Nava C, et al. Antioxidant activity of different dihydropyridines. Biochem Biophys Res Commun 2003;302:679–84.

11. Ram CV. Hypertension, possible vascular protection and lercanidipine. Expert Rev Cardiovasc Ther 2006;4:783–8.

12. Sasaki T, Maruyama H, Kase Y, Takeda S, Aburada M. Antianginal effects of lercanidipine on the vasopressin or methacholine induced anginal model in rats. Biol Pharm Bull 2005;28:811–6.

13. Yeh JL, Liou SF, Chang YP, Lin SW, Liu TS, Wu BN, et al. Isoeugenodilol inhibits smooth muscle cell proliferation and neointimal thickening after balloon injury via inactivation of ERK1/2 pathway. J Biomed Sci 2008;15:375–89.

14. Liou SF, Yeh JL, Liang JC, Chiu CC, Lin YT, Chen IJ. Inhibition of mitogen-mediated proliferation of rat vascular smooth muscle cells by labedipinedilol-A through PKC and ERK 1/2 pathway. J Cardiovasc Pharmacol 2004;44:539–51.

15. Koyama H, Olson NE, Dastvan FF, Reidy MA. Cell replication in the arterial wall: activation of signaling pathway following in vivo injury. Circ Res 1998;82:713–21.

16. Kim TJ, Jeon J, Jin YR, Son DJ, Yoo HS, Hong JT, et al. Effects of KTJ740, a novel antithrombotic agent, on platelet-derived growth factor-induced rat aortic smooth muscle cell proliferation and cell cycle progression. J Cardiovasc Pharmacol 2007;49:280–6.

17. Chen Z, Lee FY, Bhalla KN, Wu J. Potent inhibition of plateletderived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib). Mol Pharmacol 2006;69:1527–33.

18. Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem 2006;99:1553–63.

19. Seo JM, Kim TJ, Jin YR, Han HJ, Ryu CK, Sheen YY, Kim DW, Yun YP. YSK2821, a newly synthesized indoledione derivative, inhibits cell proliferation and cell cycle progression via the cell cyclerelated proteins by regulating phosphatidylinositol-3 kinase cascade in vascular smooth muscle cells. Eur J Pharmacol 2008;586:74–81.

20. Ranganna K, Yatsu FM, Hayes BE, Milton SG, Jayakumar A. Butyrate inhibits proliferation-induced proliferating cell nuclear antigen expression (PCNA) in rat vascular smooth muscle cells. Mol Cell Biochem 2000;205: 149–61.

21. Park J, Ha H, Seo J, Kim MS, Kim HJ, Huh KH, et al. Mycophenolic acid inhibits platelet-derived growth factor-induced reactive oxygen species and mitogenactivated protein kinase activation in rat vascular smooth muscle cells. Am J Transpl 2004;4:1982–90.